Physician profile
Andre Hagevik
NPI 1528039625
$5,601.21
in general payments reported to CMS, 2019-2025
31 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $1,102 · 2021: $1,502 · 2022: $313 · 2023: $751 · 2024: $359 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,129.05 | 2020-2025 | |
| Ucb, INC. | $1,097.69 | 2019-2025 | Briviact |
| Teva Pharmaceuticals USA, INC. | $562.54 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $489.56 | 2019-2025 | Crexont, Rytary |
| Acadia Pharmaceuticals INC | $440.07 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $244.75 | 2020-2021 | |
| Sk Life Science, INC. | $180.77 | 2023-2025 | Xcopri |
| Upsher-Smith Laboratories LLC | $173.05 | 2020-2021 | |
| Lilly USA, LLC | $169.80 | 2019-2021 | |
| Pfizer INC. | $141.19 | 2024-2025 | |
| Acorda Therapeutics, INC | $129.44 | 2019-2021 | |
| Argenx US, INC. | $118.75 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Lundbeck LLC | $103.93 | 2024-2025 | Rexulti |
| Biogen, INC. | $84.46 | 2019-2021 | |
| Amgen INC. | $71.90 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $70.03 | 2019-2020 | |
| Almatica Pharma LLC | $65.89 | 2021 | |
| Neurelis, INC. | $59.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.82 | 2020-2021 | |
| Allergan, INC. | $34.87 | 2019-2020 | |
| Bausch Health US, LLC | $31.63 | 2019 | |
| Promius Pharma LLC | $20.25 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.14 | 2021 | |
| Cala Health, INC. | $18.78 | 2025 | Cala Kiq |
| Neurocrine Biosciences, INC. | $17.52 | 2019 | |
| Eisai INC. | $17.52 | 2023 | |
| Ge Healthcare | $16.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.83 | 2025 | Rexulti |
| Impel Pharmaceuticals INC. | $13.20 | 2023 | Trudhesa |
| Zyla Life Sciences, INC. | $12.73 | 2020 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Hagevik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.